Literature DB >> 10480137

[The effect of polymorphisms of the angiotensin-converting enzyme and angiotensinogen genes on the phenotypic expression of Spanish patients with hypertrophic cardiomyopathy].

J López-Haldón1, J R García-Lozano, A Martínez Martínez, A Núñez-Roldán, J Burgos Cornejo.   

Abstract

BACKGROUND: Hypertrophic cardiomyopathy (HCM) has a great variability in its morphofunctional expression. This study analyzes whether angiotensin-converting enzyme (ACE) and angiotensinogen (AGT) gene polymorphisms modulate the phenotypic expression in Spanish patients with HCM. PATIENTS AND METHODS: Forty Spanish HCM patients were studied. Twenty-six out of these 40 patients belonged to 7 families with familial HCM, and the remaining 14 patients had either a sporadic HCM or a HCM with unknown family incidence. A group of 269 healthy subjects was included as control for the genotype study. Maximal wall thickness, ventricular mass and several diastolic function indexes were measured in each patient by Doppler-echocardiography. The insertion/deletion (I/D) polymorphism of ACE gene and the M235T polymorphism of AGT gene were studied in both patients and healthy subjects.
RESULTS: A higher frequency in patients than in controls was found for D allele (0.79 vs 0.64; p = 0.02) and for DD genotype (62.5 vs 41.2%; p = 0.02). Conversely, no difference was observed in M235T polymorphism between both groups. Neither DD genotype of ACE, nor TT genotype of AGT determined a greater degree of ventricular hypertrophy or a worse diastolic function in patients with HCM.
CONCLUSIONS: D allele and DD genotype are predisposing factors to express HCM. In this series of Spanish patients, I/D polymorphism of ACE and M235T polymorphism of AGT do not modify phenotypic expression of HCM.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10480137

Source DB:  PubMed          Journal:  Med Clin (Barc)        ISSN: 0025-7753            Impact factor:   1.725


  6 in total

1.  RAAS gene polymorphisms influence progression of pediatric hypertrophic cardiomyopathy.

Authors:  Beth D Kaufman; Scott Auerbach; Sushma Reddy; Cedric Manlhiot; Liyong Deng; Ashwin Prakash; Beth F Printz; Dorota Gruber; Dimitrios P Papavassiliou; Daphne T Hsu; Amy J Sehnert; Wendy K Chung; Seema Mital
Journal:  Hum Genet       Date:  2007-09-13       Impact factor: 4.132

2.  Association between angiotensinogen M235T polymorphism and hypertrophic cardiomyopathy.

Authors:  Jia-Lu Yao; Si-Jia Sun; Ya-Feng Zhou; Lang-Biao Xu; Xiang-Jun Yang; Xiao-Dong Qian
Journal:  Int J Clin Exp Med       Date:  2015-06-15

Review 3.  The influence of Angiotensin converting enzyme and angiotensinogen gene polymorphisms on hypertrophic cardiomyopathy.

Authors:  Rong Luo; Xiaoping Li; Yuequn Wang; Yongqing Li; Yun Deng; Yongqi Wan; Zhigang Jiang; Wei Hua; Xiushan Wu
Journal:  PLoS One       Date:  2013-10-25       Impact factor: 3.240

Review 4.  Genetic polymorphism of angiotensin-converting enzyme and hypertrophic cardiomyopathy risk: A systematic review and meta-analysis.

Authors:  Ye Yuan; Lin Meng; Yan Zhou; Na Lu
Journal:  Medicine (Baltimore)       Date:  2017-12       Impact factor: 1.817

5.  Angiotensinogen M235T polymorphism and susceptibility to hypertrophic cardiomyopathy in Asian population: A meta analysis.

Authors:  Zhen Zhen; Lu Gao; Qin Wang; Xi Chen; Jia Na; Xiwei Xu; Yue Yuan
Journal:  J Renin Angiotensin Aldosterone Syst       Date:  2020 Oct-Dec       Impact factor: 1.636

6.  Effect of rs4646994 polymorphism of angiotensin-converting enzyme on the risk of nonischemic cardiomyopathy.

Authors:  Jinsheng Shen; Xuesong Qian; Xiaofei Mei; Jialu Yao; Hezi Jiang; Kexin Li; Tan Chen; Yufeng Jiang; Yafeng Zhou
Journal:  Biosci Rep       Date:  2021-12-22       Impact factor: 3.840

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.